Form 4: Lexicon CEO Converts RSUs, Withholds Shares for Tax

Lexicon Pharmaceuticals CEO Michael Exton converted restricted stock units into common stock and simultaneously disposed of shares to cover tax obligations.

Summary

• Michael Exton, CEO and Director of Lexicon Pharmaceuticals, Inc. (LXRX), converted 503,263 Restricted Stock Units (RSUs) into common stock on February 28, 2026.
• Concurrently, 204,831 shares of common stock were withheld by the company at a price of $1.47 per share to satisfy tax withholding obligations related to the RSU conversion.
• Following these transactions, Exton directly owns 298,432 shares of common stock.
• Exton also directly holds 1,006,527 Restricted Stock Units.
• The Restricted Stock Units vest with respect to 1/3 of the shares on February 28 of each of the three years following the year of grant.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine and expected insider transaction related to executive compensation. The CEO retains a substantial equity stake, which is a positive for alignment with shareholders.

Positives

• The CEO is exercising previously granted equity, indicating a realization of compensation.
• The CEO retains a significant number of common shares (298,432) and a substantial amount of unvested RSUs (1,006,527), aligning his interests with shareholders.

Negatives

• A portion of the shares (204,831) were sold/withheld to cover tax liabilities, which is a common practice but reduces direct ownership.

Future Outlook

The filing indicates that the remaining 1,006,527 Restricted Stock Units will continue to vest according to their schedule, with 1/3 vesting on February 28 of each of the three years following the year of grant.

Industry Context

StockSavvy.ai notes that routine insider transactions like RSU conversions and tax-related sales are common across the biotechnology and pharmaceutical sectors, reflecting standard executive compensation practices. These transactions typically do not signal a change in company fundamentals or strategic direction.

Comparison to Industry Standards

• This type of transaction (RSU vesting and sell-to-cover for taxes) is a standard practice for executive compensation across publicly traded companies, particularly in high-growth sectors like biotech.
• Similar patterns are observed in companies like Moderna (MRNA) or Pfizer (PFE) where executives receive equity as part of their compensation packages and manage tax obligations upon vesting.
• The specific volume and price are company-specific, but the mechanism is consistent with industry norms for executive equity compensation.

Related Party Transactions

• The withholding of a portion of issued shares by the Company in satisfaction of the shareholder's tax withholding obligations is a standard related party transaction for executive compensation.

Stakeholder Impact

• Shareholders: The CEO's continued significant equity holding (both shares and RSUs) aligns his interests with shareholders. The transaction itself is a routine compensation event and does not directly impact company operations or strategy.

Next Steps

• The remaining 1,006,527 Restricted Stock Units will continue to vest according to their schedule (1/3 on February 28 of each of the three years following the year of grant).

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where the CEO converted Restricted Stock Units and sold a portion to cover tax liabilities. While the CEO retains a substantial equity stake, this specific filing does not provide new fundamental information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. It's a standard compensation event, thus a "hold" recommendation is appropriate as it doesn't present a strong buy or sell signal based solely on this filing.

Keywords

Lexicon Pharmaceuticals, LXRX, Michael Exton, Form 4, Insider Transaction, Restricted Stock Units, RSU Conversion, CEO, Equity Compensation, Tax Withholding